PFG Advisors purchased a new stake in Johnson & Johnson (NYSE:JNJ) during the fourth quarter, HoldingsChannel.com reports. The institutional investor purchased 1,816 shares of the company’s stock, valued at approximately $254,000.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Northwest Investment Counselors LLC boosted its position in Johnson & Johnson by 3.2% during the 3rd quarter. Northwest Investment Counselors LLC now owns 35,874 shares of the company’s stock worth $4,664,000 after buying an additional 1,119 shares during the period. Ramsay Stattman Vela & Price Inc. boosted its position in Johnson & Johnson by 1.5% during the 3rd quarter. Ramsay Stattman Vela & Price Inc. now owns 66,676 shares of the company’s stock worth $8,668,000 after buying an additional 993 shares during the period. Menora Mivtachim Holdings LTD. boosted its position in Johnson & Johnson by 0.7% during the 3rd quarter. Menora Mivtachim Holdings LTD. now owns 172,460 shares of the company’s stock worth $22,422,000 after buying an additional 1,250 shares during the period. Canada Pension Plan Investment Board boosted its position in Johnson & Johnson by 0.8% during the 3rd quarter. Canada Pension Plan Investment Board now owns 4,732,866 shares of the company’s stock worth $615,320,000 after buying an additional 36,300 shares during the period. Finally, IFP Advisors Inc boosted its position in Johnson & Johnson by 1.2% during the 3rd quarter. IFP Advisors Inc now owns 180,440 shares of the company’s stock worth $23,459,000 after buying an additional 2,226 shares during the period. Institutional investors own 67.40% of the company’s stock.

JNJ has been the topic of several recent research reports. Jefferies Group set a $165.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a research report on Monday, February 26th. Vetr upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $152.28 target price on the stock in a research report on Tuesday, January 23rd. Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $143.00 target price on the stock in a research report on Wednesday, March 28th. Credit Suisse Group set a $154.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a research report on Tuesday, April 17th. Finally, Deutsche Bank restated a “buy” rating on shares of Johnson & Johnson in a report on Wednesday, April 18th. Five analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have given a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $142.23.

NYSE:JNJ opened at $123.85 on Friday. The firm has a market capitalization of $336.30 billion, a PE ratio of 16.97, a P/E/G ratio of 1.92 and a beta of 0.74. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.58 and a quick ratio of 1.25. Johnson & Johnson has a twelve month low of $125.00 and a twelve month high of $125.73.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, April 17th. The company reported $2.06 earnings per share for the quarter, beating the consensus estimate of $2.00 by $0.06. The company had revenue of $20.01 billion during the quarter, compared to analyst estimates of $19.50 billion. Johnson & Johnson had a net margin of 1.58% and a return on equity of 30.65%. Johnson & Johnson’s revenue for the quarter was up 12.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.83 EPS. analysts forecast that Johnson & Johnson will post 8.13 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 12th. Stockholders of record on Tuesday, May 29th will be paid a $0.90 dividend. The ex-dividend date is Friday, May 25th. This represents a $3.60 annualized dividend and a dividend yield of 2.91%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $0.84. Johnson & Johnson’s payout ratio is currently 46.03%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.